China, Sept. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Prognostic performance of ALBI and PALBI scores in patients with hepatocellular carcinoma undergoing transarterial chemoembolization'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600132648
Registration Time: 2026/09/16
Type: Observational study
Primary Sponsor: Shenzhen Second People's Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=328846
Published by HT Digital Content Services with permission from Health Daily Digest....